Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
Search
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
Rewards and recognition
There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
Cleaning up the coast for a greener future
Employees from our Fremont site connect with nature and clean up the environment.
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
CV Disease in T2D Background
EMPA-REG OUTCOME® Trial Background
Nintedanib_in_Oncology_Backgrounder.pdf
colorectal_back_0.pdf
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
The Core of our Leitbild
Click here to find out more about Boehringer Ingelheim's core values and mission statement, highlighting our key business focuses.
Recognized as an inclusive workplace for the fifth time
Recognized as an Inclusive Workplace for the Fifth Time
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical
The Role of Endocrinologists and PCPs in Diagnosing Chronic Kidney Disease
Mohamed Eid shares his perspective on the role endocrinologists and primary care professionals play in diagnosing chronic kidney disease.
The power of patient advocacy in cancer care
Patients and advocacy organizations agree that patient empowerment is key to quality cancer care
Meet our 2023 HBA Luminary award winner honored for inspiring others
Meet our 2023 HBA Luminary award winner honored for inspiring others
New consortium EUbOPEN will provide tools to unlock disease biolog
New consortium EUbOPEN will provide tools to unlock disease biolog
Asthmatic Horse's First Inhaled Therapy | Boehringer Ingelheim US
Click here to read about Boehringer Ingelheim launching the first inhaled therapy for horses suffering with severe asthma in the United States.
Championing minds for generations both in and out of the workplace
Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC